Allos Efaproxiral ENRICH Data Needed For Brain Metastases Approval
Executive Summary
Approval of Allos Therapeutics' oncologic Excelar (efaproxiral/RSR13) should await confirmatory efficacy data from an ongoing Phase III trial, an FDA advisory committee recommended May 3